Choreo LLC Increases Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Choreo LLC raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,235 shares of the medical equipment provider’s stock after purchasing an additional 729 shares during the quarter. Choreo LLC’s holdings in Zimmer Biomet were worth $1,607,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Dunhill Financial LLC boosted its holdings in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC purchased a new stake in Zimmer Biomet in the 3rd quarter valued at approximately $28,000. Brooklyn Investment Group purchased a new stake in Zimmer Biomet in the 3rd quarter valued at approximately $35,000. R Squared Ltd purchased a new stake in Zimmer Biomet in the 4th quarter valued at approximately $63,000. Finally, Mather Group LLC. boosted its holdings in Zimmer Biomet by 100.9% in the 4th quarter. Mather Group LLC. now owns 661 shares of the medical equipment provider’s stock valued at $70,000 after purchasing an additional 332 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ZBH. Royal Bank of Canada decreased their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday. Wells Fargo & Company boosted their price target on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Oppenheimer decreased their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 15th. Truist Financial boosted their price target on Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Finally, Barclays decreased their price target on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research note on Thursday, December 12th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $124.70.

Zimmer Biomet Trading Down 1.6 %

Shares of ZBH opened at $101.01 on Friday. The stock has a fifty day moving average of $107.56 and a two-hundred day moving average of $108.16. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The company has a market capitalization of $20.11 billion, a PE ratio of 19.20, a price-to-earnings-growth ratio of 1.88 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $99.93 and a fifty-two week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. During the same quarter in the prior year, the business posted $2.20 earnings per share. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.95%. Zimmer Biomet’s payout ratio is 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.